Study protocol for a multicenter randomized controlled trial to compare radiofrequency ablation with surgical resection for treatment of pancreatic insulinoma

• Published in: Digestive and liver disease 2023-09, Vol.55 (9), p.1187-1193
• Main Authors: Crinò, Stefano Francesco, Partelli, Stefano, Napoleon, Bertrand, Conti Bellocchi, Maria Cristina, Facciorusso, Antonio, Salvia, Roberto, Forti, Edoardo, Cintolo, Marcello, Mazzola, Michele, Ferrari, Giovanni, Carrara, Silvia, Repici, Alessandro, Zerbi, Alessandro, Lania, Andrea, Tacelli, Matteo, Arcidiacono, Paolo Giorgio, Falconi, Massimo, Larghi, Alberto, Rizzatti, Gianenrico, Alfieri, Sergio, Panzuto, Francesco, Hindryckx, Pieter, Berrevoet, Frederik, Lapauw, Bruno, Lakhtakia, Sundeep, Sundaram, Sridhar, Samanta, Jayanta, Rastogi, Ashu, Landoni, Luca
• Format: Article
• Language: English
• Subjects: Acute pancreatitis; Endoscopic ultrasound; Hypoglicemia; Insulin; Neuroendocrine tumors; Pancreatic fistula
• ISSN: 1590-8658; 1878-3562
• DOI: 10.1016/j.dld.2023.06.021

Insulinoma is the most common functional pancreatic neuroendocrine tumor and treatment is required to address symptoms associated with insulin hypersecretion. Surgical resection is effective but burdened by high rate of adverse events (AEs). Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) demonstrated encouraging results in terms of safety and efficacy for the management of these tumors. However, studies comparing surgery and EUS-RFA are lacking. The primary aim is to compare EUS-RFA with surgery in term of safety (overall rate of AEs). Secondary endpoints include: (a) severe AEs rate; (b) clinical effectiveness; (c) patient's quality of life; (d) length of hospital stay; (e) rate of local/distance recurrence; (f) need of reintervention; (g) rate of endocrine and exocrine pancreatic insufficiency; (h) factors associated with EUS-RFA related AEs and clinical effectiveness. ERASIN-RCT is an international randomized superiority ongoing trial in four countries. Sixty patients will be randomized in two arms (EUS-RFA vs surgery) and outcomes compared. Two EUS-RFA sessions will be allowed to achieve symptoms resolution. Randomization and data collection will be performed online. This study will ascertain if EUS-RFA can become the first-line therapy for management of small, sporadic, pancreatic insulinoma and be included in a step-up approach in case of clinical failure.